Print Page   |   Sign In   |   Join!
Joint DVSHP/Bux-Mont January CE Dinner
View Registrations Tell a Friend About This EventTell a Friend
 

1/15/2019
When: 1/15/2019
5:30 PM
Where: Maggiano’s Little Italy
1201 Filbert St
Philadelphia, Pennsylvania  19107
United States
Presenter: Ashley DePuy, PharmD
Contact: Sejal Patel


Online registration is closed.
« Go to Upcoming Event List  

The Delaware Valley Society of Health-System Pharmacists

Established 1938

The Delaware Valley Society of Health-System Pharmacists in combination with Bux-Mont Society of Health-System Pharmacists

is proud to invite you to:

 

“Have We Found the Sweet Spot?  An Evaluation of the Clinical Use of Novel Diabetes Agents”

 

Presented by:

 

Ashley DePuy, PharmD

PGY-2 Pharmacy Ambulatory Care Resident

Temple University Hospital

Overview

You are cordially invited to the joint meeting by Delaware Valley and Bux-Mont Society of Health System Pharmacists for Live CE Presentation on January 15, 2019 at Maggiano’s Little Italy.

Location

Maggiano’s Little Italy

1201 Filbert St

Philadelphia, PA 19107

 

Parking

 

PARKWAY 12th & Filbert Garage

1201 Filbert Street

Philadelphia, PA 19107

Estimated rate is $32 for 5 hours

 

Agenda

5:30 PM – 6:00 PM:  Board Meeting (Open to all members)

6:00 PM:  Registration and Dinner

6:30 PM:  Presentation

Fees

PSHP Member: $0, included in PSHP membership
Non-Member Pharmacists: $35 or
Join Now! 

RSVP

Please register on BOTH the PSHP website and the following link: http://www.regonline.com/DVSHPJan15

Registration deadline is Thursday January 10, 2019.

Maximum of 80 registrants.

Cancellation

Please email Sejal Patel or Andy Hui at least 24 hours in advance - DVSHPmail@gmail.com

 

CE Presentation

 

Have We Found the Sweet Spot?  An Evaluation of the Clinical Use of Novel Diabetes Agents

Presented by:

Ashley DePuy, PharmD

PGY-2 Pharmacy Ambulatory Care Resident

Temple University Hospital

 

Learning Objectives:

After attending this program, the participant should be able to:

1.       Explain the rationale for using novel diabetes agents and the hierarchy of recommended usage based on clinical guidelines. 

2.       Compare and contrast the novel diabetes agents. 

3.       Recommend appropriate management strategies for hospitalized patients who utilize novel diabetes agents as an outpatient.  

 

Credits: 1.0 hours (0.10 ceu)
Type of Activity: Knowledge-based

Sponsored Presentation

 

Vonvedi® [von Willebrand factor (Recombinant)]: The First and Only Recombinant Treatment Made

Precisely for von Willebrand Disease

Presented by:

Sue Kovats-Bell BSN, RN

Senior Clinical Specialist

US Hematology

Shire

 

PROGRAM OBJECTIVES

1.       Examine important considerations in the management of bleeding in von Willebrand disease (VWD), a heterogenous bleeding disorder

2.       Share the clinical trial data (efficacy, safety, and pharmacokinetics) supporting the indications of VONVENDI in adults with VWD

3.       Describe VONVENDI supply and storage, reconstitution, dosing, and administration

Membership Management Software Powered by YourMembership  ::  Legal